Bilateral Acute Depigmentation of Iris (BADI) Post COVID Infection following Systemic Moxifloxacin Therapy.
Ocul Immunol Inflamm
; 31(6): 1210-1212, 2023 Aug.
Article
en En
| MEDLINE
| ID: mdl-35486641
PURPOSE: To report a case of BADI post Covid infection following systemic moxifloxacin therapy. METHODS: Observational case study. CASE REPORT: A 28-year-old female presented to us with complaints of redness and pain in the right eye since 5 days. History revealed use of systemic moxifloxacin for covid infection. She was managed with topical corticosteroids and cycloplegics following a diagnosis of BADI. CONCLUSION: Bilateral acute depigmentation of iris (BADI) is a rare disease entity associated with the release of iris pigments. Various underlying aetiologies have been associated with the same. Although BADI is a benign, self-limiting disorder, it needs to be differentiated with other potential severe clinical entities. SARS-CoV2 has been associated with various ocular manifestations. However, to the best of our knowledge, BADI has never been associated with COVID infection yet. We report a case of BADI in a young healthy Asian middle - aged female 3 months after an acute COVID infection.
Palabras clave
Texto completo:
1
Colección:
01-internacional
Base de datos:
MEDLINE
Asunto principal:
COVID-19
/
Enfermedades del Iris
Límite:
Adult
/
Aged
/
Female
/
Humans
Idioma:
En
Revista:
Ocul Immunol Inflamm
Asunto de la revista:
ALERGIA E IMUNOLOGIA
/
OFTALMOLOGIA
Año:
2023
Tipo del documento:
Article
País de afiliación:
India
Pais de publicación:
Reino Unido